Clinical Trial Update: Pegylated Liposomal Doxorubicin Hydrochloride, Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study evaluating pegylated liposomal doxorubicin hydrochloride, bortezomib, cyclophosphamide, and dexamethasone in refractory and various-stage multip…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (bortezomib)
• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• DEXAMETHASONE (Dexamethasone)
• Pegylated liposomal doxorubicin hydrochloride (pegylated liposomal doxorubicin)

Snippet

Sponsor: University of Washington | Conditions: Refractory Multiple Myeloma, Stage I Multiple Myeloma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2017-09-08